Skip to main content
Premium Trial:

Request an Annual Quote

'Impressed, but Puzzled'

Derek Lowe at In the Pipeline blogs about a recent post from Rob Carlson at Synthesis who recently toured a garage lab in the Silicon Valley. Carlson disclosed only vague details about the work that "biohackers" are doing in the garage; he only mentions that the participants are "screening for anti-cancer compounds," and includes two color photos depicting portions of an impressive-looking setup. Lowe writes that, looking at the photos, he can't quite imagine the scenario as it's described. "Finding compounds to screen, that must be hard when you're working where the Honda used to be parked," he writes, adding to "put me down as impressed, but puzzled." Comments on Lowe's post raised questions on the cost of reagents, and how the garage biologist obtained his/her equipment. Still, Carlson says that "garage innovation is at the heart of the way Silicon Valley works, and it is envied around the world."

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.